Mitiglinide vs repaglinide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: SUR1 (short-acting) · full Type 2 Diabetes pipeline

Mitiglinide · Glufast

Marketed by Kissei Pharmaceutical and partners

Phase 3 in Type 2 Diabetessmall molecule
Partial signal

NCT00519142 · Phase 3 · completed

The study randomly assigned 367 participants to quadruple-blinded mitiglinide-plus-metformin or metformin-plus-placebo groups, with a third mitiglinide dosing group. Its primary measure was the change in HbA1c after 24 weeks, a laboratory surrogate endpoint, and no results are available to show whether the comparison favored mitiglinide.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Reported efficacy

the change in HbA1c from randomization to endpoint (16 weeks after radomization): Change in HbA1c from randomization to Week 16 endpoint: metformin+mitiglinide -0.7% (SD 0.6) vs metformin+placebo -0.4% (SD 0.7); difference significant at P=0.002. (met)

Result source: NCT01037842

repaglinide · Prandin / NovoNorm

Rights held by Novo Nordisk

US approval withdrawn in Type 2 Diabetessmall molecule
Partial signal

NCT01562561 · Phase 3 · completed

Participants were randomly assigned to repaglinide plus insulin NPH or insulin NPH alone, but the study was open-label and the primary endpoint was HbA1c, a laboratory measure rather than a hard clinical or endoscopic outcome. Because no results are posted, it is not possible to determine whether the primary endpoint was met.

No aligned efficacy figure on record for this race.

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointMitigliniderepaglinide
HbA1c, change-0.6% vs 0.1%−0.7 vs placebowk 16 · n 118NCT02154347
3 other results
—Not posted · NCT01562561
Body weight, change (kg)—Not posted · NCT00519142—Not posted · NCT01562561
HbA1c below 7%—Not posted · NCT00519142—Not posted · NCT01562561
Fasting plasma glucose, change—Not posted · NCT00519142—Not posted · NCT01562561
3-point MACE (% with event)—Not posted · NCT00519142—Not posted · NCT01562561

HbA1c, change

Mitiglinide
-0.6% vs 0.1%−0.7 vs placebowk 16 · n 118NCT02154347
3 other results
repaglinide
—Not posted · NCT01562561

Body weight, change (kg)

Mitiglinide
—Not posted · NCT00519142
repaglinide
—Not posted · NCT01562561

HbA1c below 7%

Mitiglinide
—Not posted · NCT00519142
repaglinide
—Not posted · NCT01562561

Fasting plasma glucose, change

Mitiglinide
—Not posted · NCT00519142
repaglinide
—Not posted · NCT01562561

3-point MACE (% with event)

Mitiglinide
—Not posted · NCT00519142
repaglinide
—Not posted · NCT01562561
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

repaglinide: registry results are on file for Type 2 Diabetes, but their comparison mappings are not yet available.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Mitiglinide: 4 of 4 rows · repaglinide: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricMitiglinide
Dropout rate
—KAD-1229 (Data Through Week 52)a
NCT02154347 · Phase 4 · registry result, not featured evidence
show 4 more results
3.4%KAD-1229/KAD-1229
NCT02154347 · Phase 4 · registry result, not featured evidence
—KAD-1229/KAD-1229 (Data Through We
NCT02154347 · Phase 4 · registry result, not featured evidence
24.6%KAD-1229 / Biguanides
NCT01333592 · Phase 3 · registry result, not featured evidence · combination
13.4%KAD-1229 / DPP-4 Inhibitors
NCT01333592 · Phase 3 · registry result, not featured evidence · combination
Discontinued due to AEs
—KAD-1229 (Data Through Week 52)a
NCT02154347 · Phase 4 · registry result, not featured evidence
show 4 more results
1.7%KAD-1229/KAD-1229
NCT02154347 · Phase 4 · registry result, not featured evidence
—KAD-1229/KAD-1229 (Data Through We
NCT02154347 · Phase 4 · registry result, not featured evidence
—KAD-1229 / Biguanides
NCT01333592 · Phase 3 · registry result, not featured evidence · combination
—KAD-1229 / DPP-4 Inhibitors
NCT01333592 · Phase 3 · registry result, not featured evidence · combination
Serious AEs
10.3%KAD-1229 (Data Through Week 52)a
NCT02154347 · Phase 4 · registry result, not featured evidence
show 4 more results
—KAD-1229/KAD-1229
NCT02154347 · Phase 4 · registry result, not featured evidence
3.4%KAD-1229/KAD-1229 (Data Through We
NCT02154347 · Phase 4 · registry result, not featured evidence
7.2%KAD-1229 / Biguanides
NCT01333592 · Phase 3 · registry result, not featured evidence · combination
1.5%KAD-1229 / DPP-4 Inhibitors
NCT01333592 · Phase 3 · registry result, not featured evidence · combination
Most frequent reported AEs
a
nasopharyngitis 28% (placebo 16.7%)
cold sweat 5.1% (placebo 0%)
hunger 5.1% (placebo 1.7%)
NCT02154347 · Phase 4 · registry result, not featured evidence
show 3 more results
nasopharyngitis 11% (placebo 16.7%)
tremor 3.4% (placebo 1.7%)
back pain 2.5% (placebo 5%)
NCT02154347 · Phase 4 · registry result, not featured evidence
nasopharyngitis 43.5%
bronchitis 11.6%
γ-glutamyltransferase increase 10.1%
NCT01333592 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 25.4%
pharyngitis 9%
upper respiratory tract inflammation 7.5%
NCT01333592 · Phase 3 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Mitiglinide

HbA1c -0.61% (n=118) vs 0.05% (n=60) placebo @ 16wk
absolute change · percentage points
NCT02154347 · Phase 4 · registry result, not featured evidence
show 3 more results
-0.53% vs -0.58% nateglinide @ 12wk
NCT00461617 · Phase 3 · sponsor-reported, not registry data
-0.77% vs -0.71% nateglinide @ 20wk
NCT00461617 · Phase 3 · sponsor-reported, not registry data
-0.7% vs -0.4% placebo @ 16wk
NCT01037842 · Phase 3 · sponsor-reported, not registry data
HbA1c -0.45% (n=58) @ 52wk
absolute change · percentage points
No placebo or comparator arm
NCT01333592 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
-0.28% (n=53) @ 52wk
NCT01333592 · Phase 3 · registry result, not featured evidence · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Mitiglinide's landscape · repaglinide's landscape